61 results about "Neurodevelopmental disorder" patented technology

The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with neurodevelopmental disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.

The present invention provides methods of identifying biomarkers indicative of the presence of a neurodevelopmental disorder, including an autism spectrum disorder, in an individual, using cytometry and mass spectrometry. The invention further provides methods of using the identified biomarkers to diagnose the presence of a neurodevelomental disorder, including an autism spectrum disorder.

The invention discloses a neurodevelopmental disorder traffic safety training system and method based on VR (virtual reality) technology. The system herein comprises a virtual reality display system with an eye tracking device integrated thereto, a speech detection device, and a human action detection device. The system herein provides a series of traffic safety training tasks according to contents of the Traffic Safety Law; the traffic safety training tasks are leveled according to their difficulties; a user is trained from the low-difficulty tasks to the high-difficulty tasks. Each trainingtask includes a training/test phase; in each phase, the system herein judge the user's completion condition through the feedback data of the user, such as eye movement, speech and posture, so that next training or test content is performed. The traffic safety virtual reality technology is utilized herein; traffic safety training is performed on a patient with neurodevelopmental disorders in a virtual environment; great assistance is provided for the intervened training of the patient with neurodevelopmental disorders; the cost is effectively reduced; more patient families are benefited.

In some embodiments, the present invention provides certain compositions and methods that may be useful in the treatment and/or prevention of a neurodevelopmental disorder, such as autism or an autism spectrum disorder (ASD). In some such embodiments, compositions are provided that contain at least one fenamate active agent, such as mefenamic acid, or an analogue or derivative thereof. In some embodiments, such compositions may also comprise an additional active agent, such as gabapentin, or an analogue or derivative thereof.

The instant invention is based, at least in part, on a newly-identified proteasome-independent signaling function of ubiquitinated PSD-95. Mdm2 inhibitors, Mdm4 inhibitors, PSD-95 inhibitors, and/or enantiomers and/or derivatives thereof de-crease endocytosis via preventing PSD-95 ubiquitination, and thereby increase AMPAR, NMDAR, D1 dopamine receptor surface expression in response to a given stimulus (e.g., NMDA, Aβ). Accordingly, the invention provides methods for modulating AM-PARS, NMDARs, or D1 dopamine receptors in a neuronal cell by contacting the neuronal cell with an Mdm2 and/or Mdm4 inhibitor or PSD-95 inhibitor and/or enantiomers and/or derivatives thereof. Mdm2 and/or Mdm4 inhibitors decrease the enzymatic activity of the respective proteins, and/or interactions with their respective substrates. Mdm2 and Mdm4 inhibitors and/or PSD-95 inhibitors of the invention are contemplated for use in the treatment of neurological disorders, neurodevelopmental disorders, and psychiatric disorders. The invention also provides methods to screen for new Mdm2 and Mdm4 inhibitors and PSD-95 inhibitors and/or enantiomers and/or derivatives thereof.

A method of diagnosing, quantifying, treating, monitoring or evaluating a condition in a subject is provided. The method comprises obtaining a sample from the subject, detecting and determining the presence or quantity of one or more than one human papilloma virus (HPV) in the sample, wherein the presence or quantity of the one or more than one HPV is indicative of the presence of the condition in the subject or an increased likelihood of the subject for developing the condition when compared to a control. The condition may comprise autoimmune disorders, chronic neurodegenerative diseases, neurodevelopmental disorder, neoplasm, blood cancers such as lymphoma or leukemia, Chronic Fatigue Syndrome or Fibromyalgia.

This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.

The invention provides a VR-based neurodevelopmental disorder count calculation auxiliary training system and training method. The VR-based neurodevelopmental disorder count calculation auxiliary training system includes a VR display device, a handle, a sound playing device, a main console, and an information transmission device, wherein the handle is connected to the VR display device, and the VRdisplay device and the sound playing device are connected to the main console through the information transmission device; the main console includes a training module and an evaluation module; the training module is configured to issue a training task to the VR display device and the sound playing device in a stage training manner based on the evaluation result fed back by the evaluation module;and the evaluation module is used to evaluate the completion of the training task and feed back the evaluation result to the training module. The VR-based neurodevelopmental disorder count calculationauxiliary training system applies the virtual reality technology, combines the traditional neurodevelopmental disorder treatment experience to carry out a creative auxiliary training design, and cansatisfy the emotional demand for a patient and the interest of the product, so that the patient can learn while the impression and interest of the patient can be improved.

The present invention relates to UPR pathway inhibitors, in particular PERK and IRE-1 A inhibitors for use in the prevention or treatment of neurodevelopmental disorders, such as microcephaly caused by ZIKV.

A database of video clips is provided wherein each video clip depicts normal or abnormal behavioral patterns in children aged from birth and older or in adults. The behavior patterns in the video clip database are relevant to neurodevelopmental disorders. The behavior patterns depicted in the video clips are indexed and searchable. Also provided is a method of assessing a behavioral abnormality in the test subject. The normal and abnormal patterns for a given behavior can be compared to a test subject performing the same behavior depicted in the video library, to permit a medical professional to assess the extent of a behavioral abnormality in the test subject.

Disclosed are methods of treating a symptom selected from irritability, self-injurious behavior, intermittent explosive disorder, disruptive behavior disorder, and/or aggression in an individual diagnosed with a Neurodevelopmental Disorder (NDD) such as autism spectrum disorder (ASD). The methods comprise the step of administering to an individual in need thereof a formulation comprising paliperidone.

A method is provided which performs at least two different tests on a given child at respectively at least two different ages of said child. In the course of a first test, a first information is displayed to the child and meanwhile a controller acquires first data about eye movements of the child via an eye-tracking device and determines a first score by comparison of said first data with first pre-recorded reference data. The same is performed in the course of a second test at a second age of said child with second information which is different from the first information, hence yielding a second score. A composite score is then calculated for said child in function of at least the first and the second scores. This composite score is a more reliable indication of a risk of neurodevelopmental disorder than indicators obtained with known methods.

A method is provided in order to evaluate a risk of child having a neurodevelopmental disorder. Firstly, a first and a second information are shown simultaneously to the child at two different places on a display screen. Then the first and second information are removed from the display screen for a while and meanwhile movements of the eye of the child are tracked and recorded. Next, a third information is displayed on the display screen, at a location where the second information was previously displayed. This sequence is repeated a number of times. Next, a score for the child is established in function of the movements of his eye(s) as recorded while the first and second information were removed from the display screen. This score gives an indication of a risk of neurodevelopmental disorder with the child.

The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.

The present invention relates to iPSC produced from fibroblast obtained from a subject affected by a neurodevelopmental disorder entailing intellectual disability (ID) and/or a disorder belonging to the Autism Spectrum Disorder (ASD) and/or Schizophrenia (SZ) and uses thereof. The present invention also relates to a cortical neural progenitor cell or a terminally differentiated cortical glutamatergic or gabaergic neuronal cell or a neural crest stem cell line, a mesenchymal stem cell line produced from the iPSC or iPSC line. The invention also relates to method for identifying a compound for the treatment and/or prevention of a neurodevelopmental disorder entailing intellectual disability (ID) and/or a disorder belonging to the Autism Spectrum Disorder (ASD) and/or Schizophrenia (SZ) and to a LSD1 inhibitor or a HDAC2 inhibitor for use in the treatment of such disorders.

The present invention relates to UPR pathway inhibitors, in particular PERK and IRE-1A inhibitors for use in the prevention or treatment of neurodevelopmental disorders, such as microcephaly caused by ZIKV.

The present invention provides methods of identifying markers indicative of the risk of developing a neurodevelopmental disorder caused in part by antibody- or autoantibody-mediated damage of neural tissue, including autism spectrum disorder (ASD). The invention further provides methods of diagnosing whether an individual has a neurodevelopmental disorder, including an ASD, and methods for determining the risk that a mother's future offspring will develop an a neurodevelopmental disorder, including an ASD.

A method of providing a diagnosis for a subject having Cowden-like syndrome or PTEN germline mutations is described. The method includes the steps of: (a) obtaining a biological sample from a subject; (b) conducting a germline PTEN mutation and deletion analysis of genomic DNA from the biological sample; (c) determining the level of copy number variation in the genomic DNA; (d) comparing the level of copy number variation in the genomic DNA to a control value for copy number variation; and (e) diagnosing the subject as having an increased risk of developing a neurodevelopmental disorder if the copy number variation level is higher than the control value.

Provided is a method for identifying and reducing the risk of a female subject producing an offspring having a neurodevelopmental disorder. The method comprises detecting in the subject the presence of gut bacteria that promote Th17 cell biogenesis. If such bacteria are detected, the individual can be administered a therapy that inhibits the growth or Th17 cell biogenesis promoting activity of the bacteria, and/or reduces the activity of the Th17 cells in the gut.